Open AccessBevacizumab in recurrent glioma: Variable doses, volatile benefits
Author(s) -
Sujith Kumar Mullapally,
Pankaj Kumar Panda
Publication year - 2021
Publication title -
cancer research, statistics, and treatment/cancer research, statistics and treatment
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2590-3233
pISSN - 2590-3225
DOI - 10.4103/crst.crst_172_21
Subject(s) - bevacizumab , glioma , medicine , oncology , chemotherapy , cancer research